The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability

Br J Cancer. 2017 May 23;116(11):1436-1443. doi: 10.1038/bjc.2017.121. Epub 2017 Apr 27.

Abstract

Background: The microvascular contrast agent transfer constant Ktrans has shown prognostic value in cervical cancer patients treated with chemoradiotherapy. This study aims to determine whether this is explained by the contribution to Ktrans of plasma flow (Fp), vessel permeability surface-area product (PS), or a combination of both.

Methods: Pre-treatment dynamic contrast-enhanced MRI (DCE-MRI) data from 36 patients were analysed using the two-compartment exchange model. Estimates of Fp, PS, Ktrans, and fractional plasma and interstitial volumes (vp and ve) were made and used in univariate and multivariate survival analyses adjusting for clinicopathologic variables tumour stage, nodal status, histological subtype, patient age, tumour volume, and treatment type (chemoradiotherapy vs radiotherapy alone).

Results: In univariate analyses, Fp (HR=0.25, P=0.0095) and Ktrans (HR=0.20, P=0.032) were significantly associated with disease-free survival while PS, vp and ve were not. In multivariate analyses adjusting for clinicopathologic variables, Fp and Ktrans significantly increased the accuracy of survival predictions (P=0.0089).

Conclusions: The prognostic value of Ktrans in cervical cancer patients treated with chemoradiotherapy is explained by microvascular plasma flow (Fp) rather than vessel permeability surface-area product (PS).

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Brachytherapy
  • Capillary Permeability*
  • Carcinoma / diagnostic imaging*
  • Carcinoma / secondary
  • Carcinoma / therapy
  • Chemoradiotherapy
  • Cisplatin / therapeutic use
  • Contrast Media / pharmacokinetics*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Gadolinium DTPA / pharmacokinetics*
  • Humans
  • Lymphatic Metastasis
  • Magnetic Resonance Imaging*
  • Middle Aged
  • Plasma / physiology
  • Prospective Studies
  • ROC Curve
  • Uterine Cervical Neoplasms / diagnostic imaging*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / therapy

Substances

  • Antineoplastic Agents
  • Contrast Media
  • Gadolinium DTPA
  • Cisplatin